Business, energy, technology, markets and global industry news from Business News Today

Pharma & Biotech

PharmaDeviceNews Pharma & Biotech
plated Skin Science’s new BODY Serum brings platelet-derived exosome skincare beyond the face, targeting signs of aging, texture and hydration across the body. Representative image.
Pharma & Biotech

Rion Aesthetics expands plated Skin Science exosome platform with $338 BODY Serum

plated Skin Science takes platelet-derived exosomes beyond facial care with its $338 BODY Serum, backed by new 12-week cosmetic study data.

Read More
Genetix Biotherapeutics’ partnership with the National Football League Alumni Association highlights efforts to expand sickle cell disease awareness and improve understanding of gene therapy treatment options, including LYFGENIA. Representative image.
Pharma & Biotech

Genetix Biotherapeutics targets sickle cell treatment awareness with NFL Alumni partnership

Genetix Biotherapeutics and NFL Alumni are targeting the awareness and access gap that still limits sickle cell gene therapy adoption.

Read More
Cytovance Biologics is expanding its biologics development model with standalone analytical services covering method development, validation, GMP testing and stability programs without requiring a manufacturing contract. Representative image.
Pharma & Biotech

Cytovance widens biologics development offering after cell line and perfusion expansions

Cytovance Biologics opens GMP and non-GMP analytical testing without manufacturing contracts, widening its biologics development model.

Read More
Genentech’s $2 billion Holly Springs manufacturing facility is taking shape as Roche builds U.S. production capacity for future metabolic and obesity medicines. Representative image.
Pharma & Biotech

Genentech’s $2bn Holly Springs bet is taking shape, but the hardest manufacturing work is still ahead

Genentech’s $2 billion Holly Springs plant reaches a key milestone as Roche builds U.S. manufacturing capacity for future metabolic medicines.

Read More
Patient-derived pancreatic islet organoids and multi-omics research illustrate Greenstone Biosciences’ Breakthrough T1D-backed effort to study beta-cell vulnerability in type 1 diabetes. Representative image.
Pharma & Biotech

Can Greenstone’s patient-derived islet organoids reveal why some beta cells fail first in type 1 diabetes?

Greenstone Biosciences will build patient-derived islet organoids to study beta-cell vulnerability and identify potential type 1 diabetes drug targets.

Read More
LEO Pharma’s 10% CER revenue growth, led by expanding dermatology brands including Anzupgo and Spevigo, comes as the company increases investment in its late-stage pipeline and rare skin disease portfolio. Representative image.
Pharma & Biotech

LEO Pharma’s sales engine is accelerating, but its next growth bet is already squeezing margins

LEO Pharma’s strategic brands are surging as dersimelagon expands its pipeline, but heavier investment is putting 2026 margins under pressure.

Read More
A representative image illustrating BlossomHill Therapeutics’ BH-30643 lung cancer program as the FDA grants Fast Track designation for the investigational therapy targeting EGFR C797S-positive non-small cell lung cancer after resistance to third-generation EGFR inhibitors.
Pharma & Biotech

FDA Fast Track designation advances BH-30643 in C797S-positive lung cancer

BH-30643 gets FDA Fast Track status after early responses in C797S-positive lung cancer as BlossomHill expands the Phase 1/2 SOLARA trial.

Read More
A representative image illustrating Immatics’ anzu-cel melanoma program as the company revises the SUPRAME Phase 3 statistical plan and targets a definitive progression-free survival readout in the first half of 2027.
Pharma & Biotech

Anzu-cel Phase 3 plan changes as slower melanoma events push Immatics to single 2027 analysis

Immatics reshapes anzu-cel’s Phase 3 trial after slower PFS events, targeting one definitive H1 2027 analysis and a larger survival dataset.

Read More
A representative image illustrating Oncolytics Biotech’s pelareorep colorectal cancer research as FDA feedback outlines a potential accelerated approval path in second-line RAS-mutant, microsatellite-stable metastatic colorectal cancer.
Pharma & Biotech

Pelareorep gets clearer FDA path toward accelerated approval in RAS-mutant colorectal cancer

FDA feedback could let pelareorep move directly into a pivotal colorectal cancer expansion if randomized REO 033 data support accelerated approval.

Read More
Dunbar Pharma targets UK compounding market with EU GMP dronabinol API
Pharma & Biotech

UK already had dronabinol APIs. What makes Dunbar Pharma’s plant-derived entry different?

Dunbar Pharma brings plant-derived dronabinol API to the UK through IPS Pharma, opening a new pharmaceutical cannabinoid supply route.

Read More